Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director · Chief Scientific Officer | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 9 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F7 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 32,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 8 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2036-08-12 F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 7,031 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 7 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,094 Underlying: Common Stock · 7,031 shares Expires 2035-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 6 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,563 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 390 | $44.46 | $17,339.40 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,466 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,273 | $43.68 | $99,275.32 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,856 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.32 to $44.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,238 | $43.68 | $141,427.75 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,129 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 7,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:40 UTC Amendment | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001853529-26-000003 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 69,648 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · derivative · entry 6 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,077,717 Underlying: Common Stock · 69,648 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 130,352 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · derivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,352 shares Expires 2028-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 69,648 | $39.41 | $2,744,751.07 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,555 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 130,352 | $39.41 | $5,136,650.91 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,203 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 69,648 | $0.18 | $12,536.64 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 130,352 | $0.45 | $58,658.40 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 23:06 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001853529-25-000007 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,147,365 Underlying: Common Stock · 100,000 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 23:06 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 100,000 | $21.12 | $2,112,450.00 |
DisclosureSEC source: 0001853529-25-000007 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,400 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 23:06 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 100,000 | $0.18 | $18,000.00 |
DisclosureSEC source: 0001853529-25-000007 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:55 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001853529-25-000003 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,247,365 Underlying: Common Stock · 100,000 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:55 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 100,000 | $14.60 | $1,459,760.00 |
DisclosureSEC source: 0001853529-25-000003 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,400 F1 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.825, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:55 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 100,000 | $0.18 | $18,000.00 |
DisclosureSEC source: 0001853529-25-000003 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001562180-25-005796 · primarydocument.xml · derivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2035-08-12 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 28,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005796 · primarydocument.xml · derivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2035-08-12 F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005796 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,344 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,907 | $13.39 | $25,539.31 |
DisclosureSEC source: 0001562180-25-005796 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,400 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005796 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,005 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| May 02, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,551 | $16.45 | $25,520.46 |
DisclosureSEC source: 0001562180-25-003660 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,521 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,209 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003660 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,209 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003660 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-25-002294 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,456,580 Underlying: Common Stock · 200 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This Option was fully vested on June 27, 2021. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 200 | $30.02 | $6,004.00 |
DisclosureSEC source: 0001562180-25-002294 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,863 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:33 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 200 | $0.18 | $36.00 |
DisclosureSEC source: 0001562180-25-002294 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,200 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-25-001026 · primarydocument.xml · derivative · entry 6 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,347,565 Underlying: Common Stock · 1,200 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,200 | $30.13 | $36,153.00 |
DisclosureSEC source: 0001562180-25-001026 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,863 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 1,200 | $0.18 | $216.00 |
DisclosureSEC source: 0001562180-25-001026 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,015 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-25-001026 · primarydocument.xml · derivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,348,765 Underlying: Common Stock · 8,015 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,015 | $30.02 | $240,623.12 |
DisclosureSEC source: 0001562180-25-001026 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,863 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.0216, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 8,015 | $0.18 | $1,442.70 |
DisclosureSEC source: 0001562180-25-001026 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 22:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-24-008663 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,356,780 Underlying: Common Stock · 100,000 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested each month after June 27, 2017. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 22:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 100,000 | $27.37 | $2,737,470.00 |
DisclosureSEC source: 0001562180-24-008663 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,863 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $27.90, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 22:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 100,000 | $0.18 | $18,000.00 |
DisclosureSEC source: 0001562180-24-008663 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F2 · balance_after: Includes 2,144 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-24-006947 · primarydocument.xml · derivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,456,780 Underlying: Common Stock · 75,000 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested each month beginning on June 27, 2017. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 815 | $29.51 | $24,048.53 |
DisclosureSEC source: 0001562180-24-006947 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,719 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.56, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 74,185 | $28.25 | $2,096,052.66 |
DisclosureSEC source: 0001562180-24-006947 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,534 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $28.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 75,000 | $0.18 | $13,500.00 |
DisclosureSEC source: 0001562180-24-006947 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,968 shares purchased on May 15, 2023, 2,088 shares purchased on November 15, 2023 and 425 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 23,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006261 · primarydocument.xml · derivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 23,125 shares Expires 2034-08-12 F2 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $17.05 | $0.00 |
DisclosureSEC source: 0001562180-24-006261 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2034-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:28 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,576 | $18.91 | $29,802.16 |
DisclosureSEC source: 0001562180-24-003827 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,238 F2 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:28 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003827 · primarydocument.xml · derivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,209 Underlying: Common Stock · 5,208 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.